000			01612 a2200397 4500
005			20250516110019.0
264		0	_c20130213
008			201302s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mds260 _2doi
040			_aNLM _beng _cNLM
100	1		_aReck, M
245	0	0	_aWhat future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cSep 2012
300			_aviii28-34 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntigens, Neoplasm _ximmunology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aCTLA-4 Antigen _ximmunology
650	0	4	_aCancer Vaccines _xtherapeutic use
650	0	4	_aCarboplatin _xtherapeutic use
650	0	4	_aCarcinoma, Non-Small-Cell Lung _ximmunology
650	0	4	_aDisease-Free Survival
650	0	4	_aHumans
650	0	4	_aImmunotherapy
650	0	4	_aIpilimumab
650	0	4	_aLactoferrin _xtherapeutic use
650	0	4	_aLung Neoplasms _ximmunology
650	0	4	_aMembrane Glycoproteins _xtherapeutic use
650	0	4	_aNeoplasm Proteins _xtherapeutic use
650	0	4	_aNivolumab
650	0	4	_aPaclitaxel _xtherapeutic use
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 Suppl 8 _gp. viii28-34
856	4	0	_uhttps://doi.org/10.1093/annonc/mds260 _zAvailable from publisher's website
999			_c22048996 _d22048996